{"product_id":"auropharmans-business-model-canvas","title":"Aurobindo Pharma Limited (AUROPHARMA.NS): Canvas Business Model","description":"\u003cp\u003eAurobindo Pharma Limited stands as a pivotal player in the global pharmaceutical landscape, combining innovation with accessibility. With a robust Business Model Canvas illustrating its strategic framework—from key partnerships to diversified revenue streams—this blog post delves into how Aurobindo balances quality and affordability in its operations. Discover how this company navigates the complexities of the pharmaceutical industry and delivers value to its stakeholders, shaping healthcare accessibility worldwide.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eKey partnerships are integral to Aurobindo Pharma's operational and strategic framework. The company collaborates with various external entities to enhance its capabilities, efficiency, and market reach.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma sources its raw materials from multiple suppliers globally. In FY2023, the company reported a significant increase in its procurement costs, influenced by global supply chain disruptions and inflationary pressures. The average cost of raw materials rose by \u003cstrong\u003e12%\u003c\/strong\u003e year-over-year, reflecting the challenges in the sourcing landscape.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eSupplier Type\u003c\/th\u003e\n    \u003cth\u003eLocation\u003c\/th\u003e\n    \u003cth\u003eAnnual Spend (FY2023)\u003c\/th\u003e\n    \u003cth\u003eKey Raw Materials\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharma Intermediates\u003c\/td\u003e\n    \u003ctd\u003eChina\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$150 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eActive Pharmaceutical Ingredients (APIs)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eExcipients\u003c\/td\u003e\n    \u003ctd\u003eIndia\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$80 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eBinders, Fillers\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePackaging Materials\u003c\/td\u003e\n    \u003ctd\u003eEurope\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$60 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eBottles, Blister Packs\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma places significant emphasis on research and development (R\u0026amp;D) to drive innovation. The company has established partnerships with leading research institutions both in India and internationally. In FY2023, Aurobindo allocated \u003cstrong\u003e9% of its total revenue\u003c\/strong\u003e, approximately \u003cstrong\u003e$180 million\u003c\/strong\u003e, towards R\u0026amp;D initiatives. Collaborative projects with institutions have facilitated advancements in generics and biosimilars.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Networks\u003c\/h3\u003e\n\u003cp\u003eThe effectiveness of Aurobindo Pharma's distribution network is pivotal for its market presence. The company operates through various distribution partners in over \u003cstrong\u003e150 countries\u003c\/strong\u003e. In FY2023, Aurobindo’s revenue from international markets accounted for \u003cstrong\u003e61%\u003c\/strong\u003e of its total revenue, highlighting the importance of robust distribution ties.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRegion\u003c\/th\u003e\n    \u003cth\u003eDistribution Partner\u003c\/th\u003e\n    \u003cth\u003eMarket Share (%)\u003c\/th\u003e\n    \u003cth\u003eAnnual Revenue Contribution (FY2023)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eNorth America\u003c\/td\u003e\n    \u003ctd\u003eMcKesson Corporation\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$400 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eEurope\u003c\/td\u003e\n    \u003ctd\u003eAlliance Healthcare\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$320 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAsia\u003c\/td\u003e\n    \u003ctd\u003eLocal Distributors\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$240 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\u003cp\u003eCompliance with regulatory standards is crucial for Aurobindo Pharma's operations. The company engages with various regulatory bodies including the US FDA, EMA, and India's CDSCO. In FY2023, Aurobindo invested approximately \u003cstrong\u003e$25 million\u003c\/strong\u003e in ensuring regulatory compliance and quality assurance across its manufacturing facilities. The company received over \u003cstrong\u003e20\u003c\/strong\u003e new approvals from global regulators during this period, underscoring its strong regulatory engagement strategy.\u003c\/p\u003e\n\n\u003cp\u003eOverall, Aurobindo Pharma's key partnerships are tailored to support its mission of delivering high-quality pharmaceutical products while navigating the complexities of the global market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eAurobindo Pharma Limited engages in several critical activities that underpin its business model and deliver value to customers.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\n\u003cp\u003eAurobindo Pharma invests significantly in research and development (R\u0026amp;D) to innovate and enhance its product offerings. In the fiscal year 2022-2023, the company allocated approximately \u003cstrong\u003e7.5% of its total revenue\u003c\/strong\u003e to R\u0026amp;D activities. This equaled about \u003cstrong\u003e₹1,188 crores\u003c\/strong\u003e (approximately \u003cstrong\u003eUSD 147 million\u003c\/strong\u003e), allowing for the development of novel drug formulations and delivery systems.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing of Generic Drugs\u003c\/h3\u003e\n\n\u003cp\u003eThe manufacturing capabilities of Aurobindo are extensive, with more than \u003cstrong\u003e16 manufacturing facilities\u003c\/strong\u003e across India and the United States. In 2023, Aurobindo's production capacity was reported to be around \u003cstrong\u003e20 billion tablets\u003c\/strong\u003e annually. The company specializes in over \u003cstrong\u003e400 generic products\u003c\/strong\u003e, accounting for a significant portion of its revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eManufacturing Capacity (FY 2022-2023)\u003c\/th\u003e\n        \u003cth\u003eAnnual Tablet Production (Billions)\u003c\/th\u003e\n        \u003cth\u003eGeneric Products Offered\u003c\/th\u003e\n        \u003cth\u003eRevenue Contribution from Generics\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e20 billion\u003c\/td\u003e\n        \u003ctd\u003e20\u003c\/td\u003e\n        \u003ctd\u003e400+\u003c\/td\u003e\n        \u003ctd\u003eApproximately \u003cstrong\u003e65%\u003c\/strong\u003e of total revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eQuality Assurance and Compliance\u003c\/h3\u003e\n\n\u003cp\u003eQuality assurance is critical in the pharmaceutical industry. Aurobindo Pharma adheres to strict regulatory standards, ensuring compliance with the \u003cstrong\u003eFDA\u003c\/strong\u003e and \u003cstrong\u003eEMA\u003c\/strong\u003e. The company conducts rigorous testing and validations across its manufacturing processes. In recent audits, Aurobindo received favorable feedback, with less than \u003cstrong\u003e2%\u003c\/strong\u003e of facilities facing regulatory issues, reflecting a strong compliance record.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Sales\u003c\/h3\u003e\n\n\u003cp\u003eAurobindo employs a multifaceted marketing strategy to promote its products globally. In FY 2022-2023, the company reported a total sales revenue of approximately \u003cstrong\u003e₹19,900 crores\u003c\/strong\u003e (about \u003cstrong\u003eUSD 2.46 billion\u003c\/strong\u003e), with crucial markets including the United States, Europe, and India. The company uses a mix of direct sales and partnerships to enhance its market penetration. Notably, sales in the U.S. alone contributed about \u003cstrong\u003e40% of total revenue\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eSales Revenue Breakdown (FY 2022-2023)\u003c\/th\u003e\n        \u003cth\u003eMarket Region\u003c\/th\u003e\n        \u003cth\u003eContribution to Total Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e₹19,900 crores\u003c\/td\u003e\n        \u003ctd\u003eUnited States\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003c\/td\u003e\n        \u003ctd\u003eEurope\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003c\/td\u003e\n        \u003ctd\u003eIndia\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003c\/td\u003e\n        \u003ctd\u003eRest of the World\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThese key activities collectively reinforce Aurobindo Pharma's ability to maintain its competitive edge in the pharmaceutical industry, ensuring the delivery of quality products to meet the evolving needs of customers globally.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eAurobindo Pharma Limited's operations rely on several critical resources that enable it to deliver value effectively. These resources span advanced manufacturing facilities, a skilled workforce, intellectual property and patents, and a strong brand reputation.\u003c\/p\u003e\n\n\u003ch3\u003eAdvanced Manufacturing Facilities\u003c\/h3\u003e\n\n\u003cp\u003eAurobindo Pharma operates multiple manufacturing plants across various locations. As of the latest report, the company has a total of \u003cstrong\u003e15 manufacturing facilities\u003c\/strong\u003e, including units located in India, the United States, and Europe. These facilities are equipped with cutting-edge technology to produce a wide range of pharmaceutical products, including generics, active pharmaceutical ingredients (APIs), and specialty pharmaceuticals.\u003c\/p\u003e\n\n\u003cp\u003eIn FY 2023, Aurobindo Pharma reported a manufacturing capacity of approximately \u003cstrong\u003e500 million units\u003c\/strong\u003e across all its facilities, which contributed to a total revenue of \u003cstrong\u003e₹ 21,000 crore\u003c\/strong\u003e (approximately \u003cstrong\u003eUSD 2.5 billion\u003c\/strong\u003e). The company's continuous investment in upgrading its facilities ensures compliance with international regulatory standards and enhances production efficiency.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Workforce\u003c\/h3\u003e\n\n\u003cp\u003eAurobindo Pharma employs a skilled workforce of over \u003cstrong\u003e18,000 employees\u003c\/strong\u003e, including a substantial number of professionals with expertise in research and development, manufacturing, quality assurance, and regulatory affairs. This workforce is critical to maintaining the quality of products and ensuring the innovation necessary for competing in the global pharmaceutical market.\u003c\/p\u003e\n\n\u003cp\u003eThe company invests heavily in employee training programs, which account for approximately \u003cstrong\u003e5% of its annual HR budget\u003c\/strong\u003e. This commitment to skill development is reflected in its reduced attrition rate, which stands at \u003cstrong\u003e10%\u003c\/strong\u003e, significantly lower than the industry average of around \u003cstrong\u003e15-20%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property and Patents\u003c\/h3\u003e\n\n\u003cp\u003eAurobindo Pharma boasts a robust portfolio of intellectual property, including over \u003cstrong\u003e1,000 patents\u003c\/strong\u003e granted worldwide. As of October 2023, the company has filed applications for approximately \u003cstrong\u003e300 ANDAs (Abbreviated New Drug Applications)\u003c\/strong\u003e with the FDA. This extensive patent coverage not only protects its products but also provides competitive advantages in the marketplace.\u003c\/p\u003e\n\n\u003cp\u003eThe revenue from products protected by patents contributed to approximately \u003cstrong\u003e30% of the total revenue\u003c\/strong\u003e in FY 2023. This emphasizes the importance of intellectual property as a key resource for sustained growth and profitability.\u003c\/p\u003e\n\n\u003ch3\u003eStrong Brand Reputation\u003c\/h3\u003e\n\n\u003cp\u003eAurobindo Pharma has established a strong brand reputation, particularly in the generic pharmaceuticals sector. The company ranks among the top 10 generic manufacturers in the United States, holding a market share of around \u003cstrong\u003e4%\u003c\/strong\u003e. Its commitment to quality, affordability, and accessibility has garnered trust from healthcare providers and patients alike.\u003c\/p\u003e\n\n\u003cp\u003eAccording to the latest consumer surveys, Aurobindo Pharma's brand recognition stands at \u003cstrong\u003e75%\u003c\/strong\u003e in key markets, highlighting the effectiveness of its branding strategies. The company has also received numerous accolades for quality and innovation, further enhancing its reputation in the industry.\u003c\/p\u003e\n\n\u003ch3\u003eFinancial Overview of Key Resources\u003c\/h3\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eResource\u003c\/th\u003e\n    \u003cth\u003eDetails\u003c\/th\u003e\n    \u003cth\u003eValue\/Statistical Data\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n    \u003ctd\u003eNumber of facilities\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003c\/td\u003e\n    \u003ctd\u003eManufacturing Capacity\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e500 million units\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSkilled Workforce\u003c\/td\u003e\n    \u003ctd\u003eTotal Employees\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e18,000\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003c\/td\u003e\n    \u003ctd\u003eAnnual HR Budget for Training\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eIntellectual Property\u003c\/td\u003e\n    \u003ctd\u003eTotal Patents Granted\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1,000\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003c\/td\u003e\n    \u003ctd\u003eANDA Applications Filed\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e300\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eBrand Reputation\u003c\/td\u003e\n    \u003ctd\u003eMarket Share in the US\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003c\/td\u003e\n    \u003ctd\u003eBrand Recognition Rate\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal Revenue (FY 2023)\u003c\/td\u003e\n    \u003ctd\u003eOverall Revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e₹ 21,000 crore (USD 2.5 billion)\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eAurobindo Pharma Limited offers a unique mix of products and services that address specific customer needs, emphasizing affordability and quality in the pharmaceutical sector.\u003c\/p\u003e\n\n\u003ch3\u003eAffordable Generic Medications\u003c\/h3\u003e\n\u003cp\u003eAurobindo is one of the leading manufacturers of generic pharmaceuticals. The company reported that in FY2023, they generated approximately \u003cstrong\u003eINR 27,016 crore\u003c\/strong\u003e (around \u003cstrong\u003eUSD 3.3 billion\u003c\/strong\u003e) in revenue, with a significant portion attributed to their generic offerings. Their pricing strategy typically results in prices that are \u003cstrong\u003e30-80% lower\u003c\/strong\u003e than branded products, providing substantial savings to healthcare providers and patients.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-Quality and Reliable Products\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma's commitment to quality is demonstrated through its compliance with various international regulatory standards. As of 2023, the company holds more than \u003cstrong\u003e163 approvals\u003c\/strong\u003e from the US FDA and operates \u003cstrong\u003e16 manufacturing facilities\u003c\/strong\u003e compliant with stringent quality regulations. Their focus on quality has led to a \u003cstrong\u003e95%+ success rate\u003c\/strong\u003e in obtaining product approvals.\u003c\/p\u003e\n\n\u003ch3\u003eDiverse Therapeutic Categories\u003c\/h3\u003e\n\u003cp\u003eThe company offers a wide range of products across multiple therapeutic areas. In FY2023, Aurobindo's portfolio included over \u003cstrong\u003e300 generic formulations\u003c\/strong\u003e, covering therapeutic categories such as:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibiotics\u003c\/li\u003e\n  \u003cli\u003eAnti-retroviral drugs\u003c\/li\u003e\n  \u003cli\u003eCardiovascular medications\u003c\/li\u003e\n  \u003cli\u003eCNS medications\u003c\/li\u003e\n  \u003cli\u003eOncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe revenue by therapeutic area for FY2023 was as follows:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eTherapeutic Area\u003c\/th\u003e\n    \u003cth\u003eRevenue (INR Crore)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAntibiotics\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4,500\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e16.7%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAnti-retrovirals\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e6,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e22.2%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCNS Drugs\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3,500\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e12.9%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCardiovascular\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e18.5%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOncology\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2,500\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e9.3%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOthers\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5,516\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20.4%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eStrong Global Presence\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma has extended its operations in over \u003cstrong\u003e150 countries\u003c\/strong\u003e, significantly contributing to its revenue. In FY2023, approximately \u003cstrong\u003e60%\u003c\/strong\u003e of total sales were derived from international markets, including the US, which accounted for \u003cstrong\u003e45%\u003c\/strong\u003e of total revenue. The company's strategic partnerships and collaborations have enabled it to penetrate diverse markets effectively.\u003c\/p\u003e \n\n\u003cp\u003eThe geographical breakdown of revenue for FY2023 is as follows:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRegion\u003c\/th\u003e\n    \u003cth\u003eRevenue (INR Crore)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eUSA\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e12,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e44.4%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eEurope\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e8,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e29.6%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eIndia\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4,500\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e16.7%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRest of the World\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2,516\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e9.3%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn summary, Aurobindo Pharma Limited effectively addresses customer needs through its affordable pricing, emphasis on high quality, diverse therapeutic offerings, and significant global reach, positioning itself as a key player in the pharmaceutical industry.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eAurobindo Pharma Limited emphasizes strong customer relationships as a core part of its business model. This involves a range of interactions designed to acquire, retain, and boost sales across various customer segments.\u003c\/p\u003e\n\n\u003ch3\u003eB2B Partnerships\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma has established robust B2B partnerships globally. The company collaborates with over \u003cstrong\u003e150\u003c\/strong\u003e countries, supplying generic formulations, APIs (Active Pharmaceutical Ingredients), and contract manufacturing services. In FY 2022-23, Aurobindo reported that its revenue from B2B sales accounted for approximately \u003cstrong\u003e45%\u003c\/strong\u003e of its total revenue, amounting to approximately \u003cstrong\u003e₹8,000 crore\u003c\/strong\u003e ($965 million).\u003c\/p\u003e\n\n\u003ch3\u003eCustomer Support Services\u003c\/h3\u003e\n\u003cp\u003eCustomer support plays a significant role in Aurobindo’s strategy. The company has invested in a dedicated helpline and support team to address issues related to product inquiries, order tracking, and after-sales support. Aurobindo Pharma reported a customer satisfaction rate of \u003cstrong\u003e88%\u003c\/strong\u003e in their annual report for FY 2022-23, reflecting their commitment to customer service excellence. They have implemented various feedback mechanisms, which resulted in a \u003cstrong\u003e20%\u003c\/strong\u003e increase in resolved customer inquiries compared to the previous year.\u003c\/p\u003e\n\n\u003ch3\u003eDigital Engagement Platforms\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma has enhanced its digital engagement with customers through various platforms. The company launched a user-friendly mobile application in 2022, which has been downloaded over \u003cstrong\u003e500,000\u003c\/strong\u003e times, facilitating orders and providing product information. In the last financial year, digital sales channels contributed approximately \u003cstrong\u003e30%\u003c\/strong\u003e of total sales, equating to about \u003cstrong\u003e₹5,000 crore\u003c\/strong\u003e ($604 million). The company also maintains an active presence on social media, with over \u003cstrong\u003e100,000\u003c\/strong\u003e followers on platforms like LinkedIn and Twitter, promoting interaction and feedback.\u003c\/p\u003e\n\n\u003ch3\u003eKey Account Management\u003c\/h3\u003e\n\u003cp\u003eAurobindo’s key account management approach focuses on nurturing relationships with large clients and distributors. The company has dedicated account managers for its top \u003cstrong\u003e20\u003c\/strong\u003e clients, which include prominent pharmaceutical chains and healthcare providers. In FY 2022-23, revenues from key accounts amounted to approximately \u003cstrong\u003e₹6,500 crore\u003c\/strong\u003e ($785 million), representing a growth of \u003cstrong\u003e15%\u003c\/strong\u003e year-on-year. The focus on key accounts has led to a \u003cstrong\u003e10%\u003c\/strong\u003e increase in repeat orders from these clients within the same period.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eAspect\u003c\/th\u003e\n    \u003cth\u003eDetails\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eB2B Partnerships\u003c\/td\u003e\n    \u003ctd\u003eRevenue from B2B sales: ₹8,000 crore ($965 million) in FY 2022-23\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCustomer Satisfaction Rate\u003c\/td\u003e\n    \u003ctd\u003e88% reported satisfaction in customer service\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDigital Sales Contribution\u003c\/td\u003e\n    \u003ctd\u003e30% of total sales, approx. ₹5,000 crore ($604 million)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eKey Account Revenue\u003c\/td\u003e\n    \u003ctd\u003e₹6,500 crore ($785 million) from top 20 clients, 15% growth YoY\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAurobindo Pharma Limited remains committed to enhancing its customer relationships through continuous improvement in service quality and innovative engagement strategies, ensuring they meet the evolving needs of their clientele.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eAurobindo Pharma Limited employs a multifaceted approach to its distribution channels, ensuring an effective delivery of its pharmaceutical products.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma utilizes a dedicated direct sales force to engage healthcare professionals, hospitals, and government institutions. As of the last report, the company had a sales force of over \u003cstrong\u003e5,000\u003c\/strong\u003e professionals across various regions, focusing on promoting the company’s extensive portfolio of products.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Distributors\u003c\/h3\u003e\n\u003cp\u003eThe company relies heavily on pharmaceutical distributors to ensure its products reach a broader market. Aurobindo has partnered with more than \u003cstrong\u003e300\u003c\/strong\u003e distributors in India alone. Revenue generated through these distributors accounted for approximately \u003cstrong\u003e53%\u003c\/strong\u003e of the total sales in the domestic market, emphasizing their critical role in the supply chain.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\u003cp\u003eWith the rise of digital healthcare, Aurobindo Pharma has increased its presence on online platforms. The company reported a growth in online sales by \u003cstrong\u003e35%\u003c\/strong\u003e year-over-year, contributing to about \u003cstrong\u003e10%\u003c\/strong\u003e of the overall revenue. Aurobindo has partnerships with leading e-commerce players, enhancing its reach to consumers through online pharmacies.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma’s products are widely available through retail pharmacies, with over \u003cstrong\u003e45,000\u003c\/strong\u003e retail outlets across India. The retail channel contributes approximately \u003cstrong\u003e40%\u003c\/strong\u003e of the total revenue in the pharmaceutical segment. This extensive network not only improves accessibility but also helps in brand building among consumers.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eChannel Type\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n    \u003cth\u003eContribution to Revenue (%)\u003c\/th\u003e\n    \u003cth\u003eNumber of Partnerships\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n    \u003ctd\u003e5,000 sales professionals\u003c\/td\u003e\n    \u003ctd\u003eVariable based on sector\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmaceutical Distributors\u003c\/td\u003e\n    \u003ctd\u003e300+ distributors\u003c\/td\u003e\n    \u003ctd\u003e53%\u003c\/td\u003e\n    \u003ctd\u003e300+\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOnline Platforms\u003c\/td\u003e\n    \u003ctd\u003eGrowth: 35% YoY\u003c\/td\u003e\n    \u003ctd\u003e10%\u003c\/td\u003e\n    \u003ctd\u003eMultiple e-commerce partnerships\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n    \u003ctd\u003e45,000 retail outlets\u003c\/td\u003e\n    \u003ctd\u003e40%\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough this diversified channel strategy, Aurobindo Pharma effectively communicates its value proposition and meets the varied needs of its customer base.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eAurobindo Pharma Limited serves a variety of customer segments, each tailored to meet specific needs. Their primary segments include:\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma caters to healthcare providers, including doctors, specialists, and nursing homes. They supply a diverse portfolio of generic pharmaceuticals, ranging from antibiotics to antiretrovirals. As of the latest financial reports, Aurobindo Pharma's revenue from the U.S. generics segment reached approximately \u003cstrong\u003e₹30.05 billion\u003c\/strong\u003e (around \u003cstrong\u003e$405 million\u003c\/strong\u003e) for the fiscal year ending March 2023.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eThe company has established strategic relationships with hospitals and clinics, providing them with essential medications across various therapeutic areas. In FY23, Aurobindo extended contracts to over \u003cstrong\u003e500 hospitals\u003c\/strong\u003e in India, contributing significantly to its \u003cstrong\u003e₹115 billion\u003c\/strong\u003e (around \u003cstrong\u003e$1.55 billion\u003c\/strong\u003e) sales in the domestic market.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma supplies a wide range of products to pharmacies across India and globally. As of FY23, the company’s products are available in over \u003cstrong\u003e140,000 pharmacies\u003c\/strong\u003e in India alone. The retail pharmacy turnover is a crucial aspect of Aurobindo's strategy, with a market share in the Indian pharmacy segment of approximately \u003cstrong\u003e3.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eInternational Markets\u003c\/h3\u003e\n\u003cp\u003eAurobindo has a robust international presence, exporting its products to more than \u003cstrong\u003e150 countries\u003c\/strong\u003e. The international market contributes significantly to its revenue. In FY23, international sales accounted for \u003cstrong\u003e~66%\u003c\/strong\u003e of total revenue, amounting to roughly \u003cstrong\u003e₹75 billion\u003c\/strong\u003e (around \u003cstrong\u003e$1 billion\u003c\/strong\u003e), with the U.S. market being the largest contributor at approximately \u003cstrong\u003e₹30 billion\u003c\/strong\u003e (around \u003cstrong\u003e$400 million\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Segment\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (FY23)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n    \u003ctd\u003e50+ therapeutic areas covered\u003c\/td\u003e\n    \u003ctd\u003e₹30.05 billion (~$405 million)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n    \u003ctd\u003e500+ contracts in India\u003c\/td\u003e\n    \u003ctd\u003e₹115 billion (~$1.55 billion)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmacies\u003c\/td\u003e\n    \u003ctd\u003e140,000+ pharmacies served\u003c\/td\u003e\n    \u003ctd\u003e3.5% market share in India\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInternational Markets\u003c\/td\u003e\n    \u003ctd\u003e150+ countries\u003c\/td\u003e\n    \u003ctd\u003e₹75 billion (~$1 billion)\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThese segments are crucial in ensuring that Aurobindo Pharma can effectively address various healthcare needs and adapt its offerings to diverse markets, optimizing its value propositions accordingly.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Aurobindo Pharma Limited is a critical element in understanding its operational efficiency and overall business strategy. The company allocates its resources across various expense categories, including manufacturing, research and development, marketing, and regulatory compliance.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Expenses\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma’s manufacturing expenses include direct costs associated with the production of pharmaceuticals. For the fiscal year 2022-2023, the company reported a total manufacturing expense of approximately \u003cstrong\u003eINR 5,500 crore\u003c\/strong\u003e. This figure includes raw materials, labor, and overhead costs. The broad range of therapies manufactured by Aurobindo contributes to the scale of their manufacturing costs.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D Investments\u003c\/h3\u003e\n\u003cp\u003eResearch and development (R\u0026amp;D) play a vital role in Aurobindo Pharma’s long-term growth strategy. The company invested around \u003cstrong\u003eINR 700 crore\u003c\/strong\u003e in R\u0026amp;D during the fiscal year 2022-2023, marking an increase from \u003cstrong\u003eINR 630 crore\u003c\/strong\u003e in the previous fiscal year. This investment supports innovation and the development of new products, focusing on complex generics and specialty pharmaceuticals.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Promotional Costs\u003c\/h3\u003e\n\u003cp\u003eMarketing and promotional expenditures are essential for building the Aurobindo brand and expanding market reach. The company reported marketing costs of approximately \u003cstrong\u003eINR 1,200 crore\u003c\/strong\u003e in the fiscal year 2022-2023. This figure reflects expenses related to advertising, promotional activities, and sales force expenses aimed at increasing the company's presence in both domestic and international markets.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\u003cp\u003eRegulatory compliance costs are significant for Aurobindo Pharma, given its operations in multiple global markets. The expenses related to ensuring compliance with various health and safety regulations amounted to about \u003cstrong\u003eINR 300 crore\u003c\/strong\u003e in the fiscal year 2022-2023. These costs include maintaining quality standards for manufacturing and ongoing regulatory submissions.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCost Category\u003c\/th\u003e\n    \u003cth\u003eFY 2022-2023 (INR Crore)\u003c\/th\u003e\n    \u003cth\u003eFY 2021-2022 (INR Crore)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing Expenses\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5,500\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e5,200\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eR\u0026amp;D Investments\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e700\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e630\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarketing and Promotional Costs\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1,200\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e1,100\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e300\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e290\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn summary, Aurobindo Pharma's cost structure reveals a well-balanced approach to managing expenses across manufacturing, R\u0026amp;D, marketing, and compliance. The continuous increase in these costs reflects the company’s commitment to growth and innovation in the competitive pharmaceutical market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAurobindo Pharma Limited - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eAurobindo Pharma generates a significant portion of its revenue through product sales. For FY 2022-23, the total revenue stood at approximately \u003cstrong\u003e₹27,079 crore\u003c\/strong\u003e, with product sales contributing around \u003cstrong\u003e₹24,000 crore\u003c\/strong\u003e to this figure. The company has a diverse product portfolio, primarily in generics, branded formulations, and active pharmaceutical ingredients (APIs).\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Fees\u003c\/h3\u003e\n\u003cp\u003eThe company also garners revenue through licensing agreements, especially in the international markets. Aurobindo Pharma reported licensing income of around \u003cstrong\u003e₹300 crore\u003c\/strong\u003e in the last fiscal year, primarily from partnerships with various healthcare companies to commercialize their products globally.\u003c\/p\u003e\n\n\u003ch3\u003eContract Manufacturing\u003c\/h3\u003e\n\u003cp\u003eContract manufacturing is another vital revenue stream for Aurobindo. The company has entered into several agreements with multinational companies for producing formulations. In FY 2022-23, contract manufacturing revenue reached approximately \u003cstrong\u003e₹1,500 crore\u003c\/strong\u003e, showcasing the company's capacity to leverage its manufacturing strengths.\u003c\/p\u003e\n\n\u003ch3\u003eInternational Market Expansion\u003c\/h3\u003e\n\u003cp\u003eAurobindo has made significant strides in expanding its international presence, particularly in the US and European markets. In FY 2023, revenue from international operations accounted for around \u003cstrong\u003e60%\u003c\/strong\u003e of total sales, translating to approximately \u003cstrong\u003e₹16,000 crore\u003c\/strong\u003e. The company has strategically focused on gaining market share by introducing new products in these regions.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRevenue Stream\u003c\/th\u003e\n    \u003cth\u003eFY 2022-23 Revenue (₹ crore)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct Sales\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e24,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e89%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLicensing Fees\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e300\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eContract Manufacturing\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1,500\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInternational Operations\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e16,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45737627484309,"sku":"auropharmans-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/auropharmans-business-model-canvas.png?v=1739160209","url":"https:\/\/dcf-model.com\/es\/products\/auropharmans-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}